прорыв в лечении причины муковисцидоза, самых его расространенных мутаций.
Dear Friend,
We have good news to share with you. This morning, Vertex Pharmaceuticals announced positive final results from a Phase 2 combination study of Kalydeco™ and a potential cystic fibrosis drug called VX-809.
Cystic fibrosis patients with two copies of the most common mutation, Delta F508, showed significant improvements in lung function while taking the combination therapy.
Based on this data, Vertex plans to begin a pivotal study of the combination treatment in those with two copies of Delta F508 in early 2013. Vertex also plans to conduct additional studies of VX-809 and Kalydeco in patients with one copy of the Delta F508 mutation and another CF mutation.
We are proud to have played a role in the development of Kalydeco and VX-809, providing significant scientific, clinical and financial support.
We still have work to do, but this is a significant step forward, and it would not be possible without your support.
Thank you for all you do.
Sincerely,
Cystic Fibrosis Foundation
We have good news to share with you. This morning, Vertex Pharmaceuticals announced positive final results from a Phase 2 combination study of Kalydeco™ and a potential cystic fibrosis drug called VX-809.
Cystic fibrosis patients with two copies of the most common mutation, Delta F508, showed significant improvements in lung function while taking the combination therapy.
Based on this data, Vertex plans to begin a pivotal study of the combination treatment in those with two copies of Delta F508 in early 2013. Vertex also plans to conduct additional studies of VX-809 and Kalydeco in patients with one copy of the Delta F508 mutation and another CF mutation.
We are proud to have played a role in the development of Kalydeco and VX-809, providing significant scientific, clinical and financial support.
We still have work to do, but this is a significant step forward, and it would not be possible without your support.
Thank you for all you do.
Sincerely,
Cystic Fibrosis Foundation